Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

BioEclipse Therapeuticstm to Participate in the Sachs Annual Biotech in Europe Forum


MOUNTAIN VIEW, Calif., Sept. 18, 2020 /PRNewswire/ -- BioEclipse Therapeuticstm, a private clinical-stage biopharmaceutical company developing first-in-class, curative immuno-oncology therapeutics, announced today that its CEO and founder Pamela Contag, Ph.D., and CFO Ben Carter will participate in the Sachs 20th Annual Biotech in Europe Forum, taking place September 21?24, 2020 via a virtual platform.

Dr. Contag will host virtual one-on-one meetings with investors and potential partners to discuss BioEclipse's business strategy and highlight recent corporate achievements, as well as anticipated milestones in its clinical program for CRX100, BioEclipse's lead investigative candidate. Institutional investors are invited to request meeting times.

To schedule a one-on-one meeting, please contact Dr. Contag or Mr. Carter at BioEclipse Therapeutics.

CRX100 is an intravenously delivered cancer therapy designed to target and destroy multiple cancer types and to prevent disease recurrence. It only targets tumor cells, leaving healthy tissue untouched, but it has the ability to reach tumors throughout the body.  This means CRX100 holds promise for metastatic disease treatment with limited toxicity. BioEclipse plans to initiate a Phase 1 clinical trial in therapy-refractory solid tumors before year end.

About BioEclipse Therapeuticstm
BioEclipse Therapeuticstm is an emerging, clinical-stage biopharmaceutical company committed to delivering first-in-class, curative immuno-oncology therapeutics to patients with cancer. Our focus is on currently untreatable cancers where our unique multi-mechanistic combination approach could address needs of patients with cancers believed to be untreatable. BioEclipse Therapeuticstm is preparing to initiate Phase I clinical trials with, CRX100, a patented, first in class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being developed to deliver potentially curative treatment to patients over a broad range of tumor types, including some rare pediatric cancers. For more information, visit www.bioeclipse.com.

Contacts:
Tiberend Strategic Advisors, Inc. 
Miriam Miller (Investors)
212-375-2694
mmiller@tiberend.com 
Johanna Bennett (Media)
212-375-2686
jbennett@tiberend.com

SOURCE BioEclipse Therapeutics


These press releases may also interest you

at 07:30
Invitae Corporation , a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m....

at 07:11
AM TRACE LLC, a national, private-sector leader that helps state and local governments accelerate the effectiveness of their public health response to the COVID-19 pandemic through Case Investigation and Community Contact Tracing, announced the City...

at 07:05
Ocular Therapeutixtm, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter financial...

at 07:01
/NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION/ THIS IS AN ANNOUNCEMENT FALLING UNDER...

at 07:00
Note: All times local Ottawa, Ontario Private meetings. 11:30 a.m.     The Prime Minister will make an announcement and hold a media availability. President of the Treasury Board Jean-Yves Duclos, President of the Queen's Privy Council for Canada...

at 07:00
Milestone Pharmaceuticals Inc. , a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the pricing of its previously announced...



News published on 18 september 2020 at 07:30 and distributed by: